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Abstract
Background: The potential benefits of coordinating infectious disease eradication programs that use campaigns
such as supplementary immunization activities (SIAs) should not be over-looked. One example of a coordinated
approach is an adaptive “sequential strategy": first, all annual SIA budget is dedicated to the eradication of a single
infectious disease; once that disease is eradicated, the annual SIA budget is re-focussed on eradicating a second
disease, etc. Herd immunity suggests that a sequential strategy may eradicate several infectious diseases faster than
a non-adaptive “simultaneous strategy” of dividing annual budget equally among eradication programs for those
diseases. However, mathematical modeling is required to understand the potential extent of this effect.
Methods: Our objective was to illustrate how budget allocation strategies can interact with the nonlinear nature of
disease transmission to determine time to eradication of several infectious diseases under different budget
allocation strategies. Using a mathematical transmission model, we analyzed three hypothetical vaccine-preventable
infectious diseases in three different countries. A central decision-maker can distribute funding among SIA
programs for these three diseases according to either a sequential strategy or a simultaneous strategy. We
explored the time to eradication under these two strategies under a range of scenarios.
Results: For a certain range of annual budgets, all three diseases can be eradicated relatively quickly under the
sequential strategy, whereas eradication never occurs under the simultaneous strategy. However, moderate
changes to total SIA budget, SIA frequency, order of eradication, or funding disruptions can create
disproportionately large differences in the time and budget required for eradication under the sequential strategy.
We find that the predicted time to eradication can be very sensitive to small differences in the rate of case
importation between the countries. We also find that the time to eradication of all three diseases is not necessarily
lowest when the least transmissible disease is targeted first.
Conclusions: Relatively modest differences in budget allocation strategies in the near-term can result in
surprisingly large long-term differences in time required to eradicate, as a result of the amplifying effects of herd
immunity and the nonlinearities of disease transmission. More sophisticated versions of such models may be useful
to large international donors or other organizations as a planning or portfolio optimization tool, where choices
must be made regarding how much funding to dedicate to different infectious disease eradication efforts.
Background
Infectious diseases have long imposed a considerable
burden on human populations around the world [1-3].
However, the only vaccine-preventable infection to have
been globally eradicated to date is smallpox. Although
the smallpox vaccine was available starting in the 19
th
century, smallpox was only eradicated in 1977 after a
final, intensive 10-year push by the World Health Orga-
nization that required global coordination of control
efforts [3].
Vaccine-preventable paediatric infectious diseases such
as polio, measles and pertussis continue to cause signifi-
cant morbidity and mortality worldwide. While polio
has been successfully eradicated from the western
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(Nigeria, Afghanistan, India, and Pakistan) [4]. An esti-
mated 1 in 200 polio infections lead to irreversible
paralysis and 5-10% of these individuals will die due to
breathing complications resulting from this paralysis
[5,6]. Deformities and paralysis acquired as a result of
polio infection have lasting lifelong implications. Initial
symptoms include fever, headache, fatigue and vomiting
[7]. Some of these initial symptoms are similar to those
of common ailments such as influenza, making infection
control difficult. Measles likewise is responsible for con-
siderable morbidity and mortality. Most measles-related
deaths are due to complications such as dehydration as
a result of diarrhea, or pneumonia [7-10]. Pertussis
(whooping cough) infection is most serious in infants
under 6 months of age: 1 in 200 of these infants will die
as a result of complications, such as brain damage
[6,10]. Pertussis can be contagious up to three weeks
after infection, and it is most contagious during the first
two weeks [11,12]. Symptoms at this stage closely
resemble those of a common cold, meaning a person
may not notice they are infected with pertussis, and can
unknowingly transmit the pathogen [12].
Immunization for many paediatric infectious diseases
in lower income countries is delivered not only through
routine immunizations, as in higher income countries,
but also through large-scale campaigns known as sup-
plementary immunization activities (SIAs) [4,5,13]. SIAs
improve health outcomes in low-income countries by
preventing the build-up of the susceptible population
and thereby preventing outbreaks [14,15]. At the time of
submission of this paper, polio is close to eradication
and remains endemic in only four countries (India,
Nigeria, Afghanistan, and Pakistan), thanks largely to
SIAs [4]. However, as long as a transmissible disease
remains endemic in any one country, it can resurface in
other countries through case importation.
SIAs also provide a platform for delivering other inter-
ventions such as Vitamin A supplements; insecticide
treated bednets (ITNs) for the prevention of malaria;
and anti-viral drugs. A recent economic study concludes
that integrating ITN distribution for malaria prevention
into measles vaccination campaigns can achieve greater
and more equitable coverage of ITN, while also reducing
the total cost of bednet procurement from US $3.42 per
bednet distributed to US $0.32 per bednet distributed
[14]. This illustrates the potential synergies of coordinat-
ing infection control programs for different infectious
diseases.
Vaccinating every single person in the world is
implausible, and hence eradication of an infectious dis-
ease requires the indirect protection offered to unvacci-
nated individuals through herd immunity. Disease
transmission models can capture herd immunity effects
and thus be used to project the time to eradication
under different immunization scenarios. More generally,
they can be used to project a broad range of future
health or economic outcomes under different possible
intervention strategies.
A number of transmission models of routine and cam-
paign immunization in low-income settings have been
developed [16-22]. Most of these focus on a single dis-
ease and a single intervention in a single region or
country. For instance, a mathematical model has been
used to explore the possible implications of various HIV
control strategies, such as spreading donor money
evenly over a 20-year period versus spending the same
amount of money up-front over a 5-year period in an
effort to eradicate HIV [16]. The authors’ model sug-
gests that spending all funds up-front over a 5-year per-
iod could eradicate HIV and result in significant cost-
savings, whereas under the same conditions HIV could
not be eradicated under the 20-year strategy. The model
illustrates how budget allocation strategies can interact
with the inherent nonlinearities of disease transmission
(and in particular, herd immunity effects) to determine
outcomes.
Examples of transmission models for studying the
impact of coordinated efforts to control multiple infec-
tious diseases are more rare. However, a model has
been used to analyze priority shifting in the funding of
programs for two hypothetical vaccine-preventable
infectious diseases [17]. The authors concluded that a
re-allocation strategy based on a goal of eradication
(where all funds are focused to one disease until it is
eradicated, at which points funds are re-allocated to
focus on the remaining disease) can often achieve better
long-term outcomes than a strategy that allocates
resources based on which disease has the highest cur-
rent prevalence ("fire-fighting”) or a simultaneous strat-
egy that divides resources equally among the control
programs.
Here, we explore such re-allocation strategies using a
transmission model for three hypothetical infectious dis-
eases (A, B and C) against which SIAs are conducted in
each of three low-income countries that have not yet
eliminated the diseases. We use a transmission model to
project the time required to eradicate each of these dis-
eases under various possible SIA budget allocation stra-
tegies. For each country, a total budget is allocated for
use in SIAs for all three infectious diseases. We assume
it is possible for a central decision-maker to allocate dif-
ferent amounts of money each year among SIA pro-
grams for the three diseases. For instance, a decision-
maker can adopt a “sequential strategy” of initially allo-
cating all SIA budget to Disease A until it is eradicated
(meaning no budget is available for SIAs against Dis-
eases B and C during this period, but routine coverage
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dicated, the annual SIA budget can be dedicated to Dis-
ease B until it is eradicated, and then finally to Disease
C. Herd immunity suggests that all three diseases may
be eradicated more quickly under this approach than
under approaches that do not strategically re-allocate
among the SIA programs. Alternatively, a decision-
maker can opt for a “simultaneous strategy” of simulta-
neously funding SIAs for all diseases.
Our analysis differs from that of Ref. [17] in that it
explores three diseases in three populations instead of
two diseases in one population; it includes case importa-
tion; it systematically explores how model predictions
depend on input parameter values; it explores scenarios
such as (1) constant versus increasing routine immuni-
zation coverage, and (2) what happens when SIA budget
for all three diseases is interrupted for a period of time
such as due to lack of donor funds. Our results gener-
ally confirm the previous finding that sequential strate-
gies can work better than simultaneous strategies for
certain budget levels. However, we also find that the
relative effectiveness of the sequential strategy can
depend sensitively on details such as how much case
importation there is between the three countries, how
much budget is available, and the order in which the
diseases are eradicated.
Our model structure and assumptions are deliberately
simplified, because our goal is to illustrate how budget
allocation strategies can interact with the nonlinear nature
of disease transmission and herd immunity effects to drive
surprisingly large and disproportionate differences in the
time required to eradicate infectious diseases under differ-
ent budget allocation strategies. A fuller evaluation of this
type for use in formulating policy would require greater
attention to how transmission is modelled and how costs
and health outcomes are estimated and compared. It
would also require incorporating the restrictions and reali-
ties of how international donors support disease control
programs, and a fuller accounting for the disruption to
health services delivery caused by moving budget between
programs. Notwithstanding, the herd immunity effects
captured by our simple model are shared by more com-
plex infectious disease transmission models, therefore a
more sophisticated analysis might share some of the same
qualitative features we will highlight here.
Methods
Mathematical Model
Our model structure and parameter values are intended
to represent three hypothetical paediatric infectious dis-
eases. More sophisticated country-specific and disease-
specific versions of such transmission models would be
required to address the issue of optimal eradication stra-
tegies for actual infectious diseases
We use a compartmental transmission model. This
type of model has been shown to agree reasonably well
with time series of infection incidence many paediatric
infectious diseases even when age structure is not
included [12,20,23,24]. Individuals can be Susceptible,
Infectious, Recovered, or Vaccinated with immunity,
h e n c ew er e f e rt oi ta saS I R Vm o d e l .T h em o d e l
assumes long-term natural immunity, which is a reason-
able approximation for many paediatric infections
[12,24]. The model equations for a given disease in
country k are given by
dSk
dt
= μ(1 − ϕε)Nk − βSk
Ik
Nk
− μSk
dIk
dt
= βSk
Ik
Nk
− γIk + mIa + mIb − 2mIk − μIk
dRk
dt
= γIk − μRk
dVk
dt
= μϕεNk − μVk
(1)
where all model parameters and associated baseline
values are defined in Table 1 [7,8,12,25-28]. These equa-
t i o n sr e p r e s e n tt h ec h a n g eo v e rt i m eo ft h en u m b e ro f
individuals who are susceptible (Sk), infectious (Ik),
recovered (Rk) and vaccinated (Vk)i nc o u n t r yk.T h e
parameters are generally country-specific and disease-
specific (although subscripts are omitted for clarity).
Parameters include the per capita birth rate (μ), the per
capita all-causes death rate (also μ), the rate at which
individuals recover from infection (g), and the efficacy of
vaccination (ε). Vaccine was assumed to have “all or
nothing” efficacy. The bSI/N term describes the trans-
mission of infection from infected to susceptible persons
and means that the rate at which new infections are cre-
ated is proportional to the product of the number of
infected and susceptible individuals. The mIa and mIb
terms represent case imports to country k from the
other two countries a and b,w h e r em is the per capita
import rate. Conversely, the -2 mIk term represents
cases leaving country k and being exported to countries
a and b. For simplicity, we have assumed the per capita
importation rates to be the same between countries
even though they will generally vary, and will be higher
for countries in close geographic proximity. The trans-
mission rate, b, was computed from estimates of the
recovery rate, g, and the basic reproductive number, RO,
from the relation b≈gRO for the three diseases [12]. We
defined an infection as eliminated in a country if the
number of infectious persons dropped below one, in
which instance the number of infectious persons was set
to zero. This was done to capture some of the effects of
stochastic extinction; a complete accounting for such
stochastic effects would require a stochastic model. We
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old in sensitivity analysis. If the infection is eliminated
in all three countries, it is considered eradicated. We
did not include a 3-year waiting period before elimina-
tion is certified in a given country and resources are
switched to a different immunization program, although
this should not significantly change the relative success
of the sequential versus simultaneous strategies. This
model neglects disease-related deaths, however, this will
not change the qualitative feature of the dynamics or
the time to eradication since death often occurs after
the period of peak infectiousness for many paediatric
infectious diseases.
We assume that routine vaccination is administered in
the first year of life. The fraction of the population who
are successfully vaccinated under routine vaccination is
defined by the εN term in the equations, where  is
the rate at which individuals are vaccinated and N is the
population size, which together with μ determines the
number of births and hence the number of individuals
vaccinated. Immunization campaigns (SIAs) are
modelled by moving individuals from the susceptible to
the vaccinated compartment at the time of the cam-
paign, according to assumed SIA coverage and vaccine
efficacy. We assumed that SIAs could be conducted
rapidly in a given country, since they are usually con-
ducted as large-scale campaigns. Hence, SIAs were mod-
elled as a “pulse” to the differential equations, resulting
in the following instantaneous changes to the compart-
ment sizes:
Sk → Sk − SkϕSIAε
Vk → Vk + SkϕSIAε
where SIA is the vaccine coverage in the SIA. Vaccine
coverage and efficacy vary according to infectious dis-
ease and SIA program (i.e. the vaccine for some diseases
will intrinsically have a higher efficacy than others). We
note that real-world SIAs involve choices about which
age groups to immunize, but our model is not age-
structured, hence the implicit assumption that vaccine is
administered regardless of age.
Assumptions about study diseases and populations
Our three hypothetical diseases were Disease A (low
transmissibility), Disease B (higher transmissibility,
shorter infectious period), and Disease C (higher trans-
missibility, longer infectious period). The basic repro-
ductive numbers R0 for Diseases A, B, and C were taken
to be 6, 15, and 14, respectively [12]. We used India,
Nigeria and Afghanistan as our three case study coun-
tries, corresponding respectively to one country each of
large, moderate and small population size in relative
terms.
Vaccine coverage and SIA budget scenarios
We designed simplified scenarios for the implementa-
tion of immunization programs. We introduced routine
vaccination for all three diseases in all three countries in
1960. In 1990, we introduced SIAs in addition to routine
vaccination; a total annual budget was allocated for SIAs
for all three diseases in all three countries. Each country
was allocated their own SIA budget in direct proportion
to their population size, and each country divided this
allocated budget equally among SIAs for the three infec-
tious diseases. (We note that in practice, the assumption
that budget for SIAs is divided equally across the three
diseases may not hold. However, the actual criteria for
how budget is allocated across SIAs may be numerous
and complex, hence we opted for this simplifying
assumption.) The budget for each SIA program in each
country was translated into SIA coverage by dividing the
budget by the unit vaccine costs in Table 2 to obtain
number of doses administered per SIA. We assumed
that both susceptible and naturally immune individuals
Table 1 Model parameters
Parameter Definition Value(s) References
Disease-specific parameters
 Routine vaccination
rate
0.5/year assumed
g Recovery rate Disease A: 1/19 per
day*
Disease B: 1/14 per
day*
Disease C: 1/30 per
day*
[12]
RO Basic reproductive
number
Disease A: 6*
Disease B:15*
Disease C: 14*
[12]
ε Efficacy of vaccine after
1 dose
Disease A: 99%*
Disease B: 95%*
Disease C: 90%*
[7,8,25]
Country-specific parameters
m Case importation rate 0.0001 per year per
capita in all
countries
assumed
μ Birth/death rate
(per 1, 000 per year)
[As of 2009]
India: 21.72/1000/yr
Nigeria: 36.65/1000/
yr
Afghanistan: 38.37/
1000/yr
[25-28]
N Total population
[As of 2009]
India: 1, 156, 897,
766
Nigeria: 149, 229,
090
Afghanistan: 28,
395, 716
[25-28]
*The parameter values for diseases A, B and C are hypothetical but plausible,
being based on values for common paediatric infections such as measles,
pertussis, and polio. (However we note that R0 can vary between populations
and over time, and efficacy for oral polio vaccines can be as low as 50%).
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include the cost of the vaccine and cost of vaccine
administration. Vaccine costs varied from country to
country, and are dependent on which vaccine is being
given. Table 2 shows the assumed prices of each vaccine
in India, Nigeria and Afghanistan, which were estimated
or taken directly from the literature [10,13,14,29-32].
SIAs were assumed to occur every 3 years in the base-
line scenario, and budget money from years where no
SIA was conducted could be saved and used for SIAs in
subsequent years. Hence, under certain values of the
annual budget, the SIA coverage might vary depending
on whether SIAs were conducted every 2, 3 or 4 years.
We note that assumed budgets in the model reflect only
the budgets for SIA programs, and not for routine
immunization. We also note that prices can vary accord-
ing not only to vaccine type but also country and type
of vaccine delivery program, and that Table 2 required
making assumptions about unit costs when good coun-
try-specific data were not available.
Starting in 2010, we distinguished two possible strate-
gies. Under the “simultaneous strategy”, funding con-
tinues to be divided equally among the three diseases in
the same way as it was done between 1990 and 2009 (i.
e. efforts to eradicate the infectious diseases continue to
occur concurrently). In contrast, under the “sequential
strategy”, budget reallocation starts in 2010 such that all
SIA funding in each country is dedicated to SIAs for
one disease until that disease is eradicated; once the first
disease is eradicated, then beginning in the next round
of SIAs, all SIA funding for the country is then dedi-
cated to the next disease until that is eradicated; once
the second disease is eradicated then all funding is dedi-
cated to the last disease commencing in the subsequent
round of SIAs until it is eradicated. All countries adopt
the same order of eradication, and all countries maintain
a routine vaccination rate of 50% for all three diseases
during this time. Given that all funding goes into eradi-
cation of one disease at a time, at any given time at
least two diseases are receiving no funding, meaning no
SIAs would occur for them during this period. In the
baseline scenario we considered eradication in the order
Disease A, B, then C; other orders of eradication were
also analyzed.
Simulations
It is possible to solve the equilibrium of the SIRV equa-
tions analytically, resulting in a simple expression for
the vaccine coverage required to eliminate an infection
in a population. When there is enough budget to exceed
this threshold for all three diseases in all three popula-
tions, then all three diseases could eventually be eradi-
cated with a simultaneous strategy [17]. If less budget is
available, a sequential strategy might work better, and in
this case the SIRV equations need to be simulated to
determine how much time is required to eradicate the
infection under simultaneous versus sequential
strategies.
We simulated the model using MATLAB R2008a.
There were 9 sets of equations in total, of the same
structure as equation system (1): three for each disease
in each of the three countries. The initial conditions
were such that the number of susceptible, infected, and
v a c c i n a t e dp e r s o n sf o ras i n g l ed i s e a s ei nag i v e nc o u n -
try were equal to 5%, 0.1%, and 0% of the country’s total
population, respectively (the remainder were recovered).
However, the simulation was run for a sufficient amount
of time for the prevalence of each infection in each
country to come to equilibrium by the year 1960 when
routine immunization begins. The routine vaccination
rate was 0.5 per year, each year, in the baseline scenario,
although we explored the case where it increases at 0.01
per year from an initial level of 0.5 per year from 2010
onward in a sensitivity analysis.
Results
The impact of changes in vaccine coverage in 1960
(introduction of routine vaccination) and 1990 (intro-
duction of SIAs) can be seen in time series of disease
prevalence of all three diseases in all three countries
under the simultaneous strategy (Figure 1). Baseline
parameter values (Table 1) are used for this simulation
as well as subsequent simulations, except where other-
wise noted. In 1960, the introduction of routine vaccina-
tion induces transient oscillations in infection prevalence
until the model dynamics “settle down” to a new equili-
brium prevalence that is lower than the pre-vaccine era
prevalence in all three countries. In 1990, the introduc-
tion of SIAs with a total annual budget of US $180 mil-
lion for all three SIA programs in all three countries
results in further reduction in prevalence for all three
infections: Disease B and Disease C remain endemic in
all three countries, and Disease A is eliminated from
Table 2 Vaccination price for each country by disease
Price of Vaccination ($US) References
Disease A* India: 0.31
Nigeria: 1.15
Afghanistan: 0.31
[13,29,30]
Disease B* India: 0.64
Nigeria: 0.76
Afghanistan: 0.78
[14,10,31]
Disease C* India: 0.62
Nigeria: 0.62**
Afghanistan: 0.62**
[32]
* The parameter values for diseases A, B and C are hypothetical but plausible,
being based on values for common paediatric vaccines such as monovalent
measles vaccine, dTaP and oral polio vaccine.
** Assumed value due to lack of data.
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very low levels in Nigeria. Hence, under the simulta-
neous strategy for baseline parameter values, no disease
is eradicated for the foreseeable future. Therefore, a
total annual budget of US $180 million is used as our
baseline parameter value, to provide a meaningful con-
trast to outcomes under the sequential strategy versus
the simultaneous strategy. This value is on the same
order of magnitude as immunization program budgets
in some countries [16,21,29,30].
The differences in epidemic patterns between the
t h r e ec o u n t r i e so b s e r v e di nF i g u r e1a r ed u et od i f f e r -
ing birth rates (Table 1) and vaccine unit costs (Table
2). The time between outbreaks is longer in India (Fig-
ure 1a) than in Nigeria (Figure 1b) and Afghanistan
(Figure 1c) because India has a lower birth rate than
either Nigeria or Afghanistan (Table 1). Similarly, Dis-
ease A persists for longer in Nigeria (Figure 1b) than
in India (Figure 1a) or Afghanistan (Figure 1c) because
the vaccine for Disease A costs significantly more for
N i g e r i at h a nf o rI n d i ao rA f g h a n i s t a n( T a b l e2 ) .T h e
way that elimination is defined may also be relevant:
we considered a disease as eliminated in a country if
prevalence fell below one person, and this benchmark
is harder to reach in a larger population such as that
of India.
Figure 1 Time series of prevalence under simultaneous strategy. Disease prevalence in India (a), Nigeria (b), and Afghanistan (c) according
to simulations, where routine vaccination is introduced in 1960 and SIAs are introduced in 1990. Cumulative incidence for India (d), Nigeria (e),
and Afghanistan (f) is also shown for the same scenario.
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annual budget of US $180 million, the time evolution
is the same as for the simultaneous strategy until bud-
get reallocation begins in 2010. Under the sequential
strategy, the model predicts a very different time evo-
lution of future incidence (Figure 2). All three diseases
are eradicated by 2030: Disease A is eradicated first in
2021, followed by Disease B in 2024, and finally Dis-
ease C in 2030 (by comparison, under the simulta-
neous strategy for the same budget, no disease is
eradicated in the foreseeable future). Figure 3 shows a
time series of SIA vaccination coverage in each coun-
try under the sequential strategy, and the changing
vaccine coverage due to budget re-allocation is
apparent.
This example demonstrates how budget reallocation
strategies can take advantage of herd immunity to
speed eradication of all three diseases. However, there
are tradeoffs: in the period where SIA funds are being
dedicated entirely to Disease A, the average prevalence
of Diseases B and C increases for a period after budget
reallocation begins in 2010. This is seen in Figure 2
versus Figure 1 in the decade after 2010, where recur-
rent epidemic spikes are present in both figures but
the average prevalence of Diseases B and C is higher
i nF i g u r e2t h a ni nF i g u r e1 .T h i si sa l s os e e ni np l o t s
Figure 2 Time series of prevalence under sequential strategy. Predicted disease prevalence in India (a), Nigeria (b), and Afghanistan (c), such
that routine vaccination is introduced in 1960, SIAs begin in 1990, and reallocation occurs according to the sequential strategy in 2010,
eradicating diseases in the order: A, B, then C. Cumulative incidence for India (d), Nigeria (e), and Afghanistan (f) is also shown for the same
scenario.
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in Figures 1 and 2.
We considered a disease to be eliminated in a country
once prevalence in that country fell below 1 person. To
test the impact of this assumption, simulations were
also conducted using elimination thresholds of 2, 0.1
and 0.01 persons for the baseline sequential strategy.
We found that the year of eradication of all three dis-
eases changed from 2030 (for the baseline scenario
where the threshold is 1 person) to 2024, 2060 and
2066 under these two thresholds, respectively. Hence,
the cutoff for defining elimination in a country has
some impact on model predictions although the differ-
ences are not large enough to change our conclusion
that the sequential strategy outperforms the simulta-
neous strategy, at least for this level of annual budget.
In the following subsections we explore a wider range
of possibilities, including what happens under: (1) varia-
tion in the total annual SIA budget; (2) variation in the
frequency of SIAs; (3) variation in the order of eradica-
tion; (4) interruption in SIA budgets; (5) increasing rou-
tine vaccination over time; and (6) varying case
importation rates.
Impact of varying total budget
We varied the annual SIA budget to understand the
impact of budget on time to eradication under the simul-
taneous strategy versus the sequential strategy. For the
sequential strategy, there is a minimum annual budget of
approximately $170 million below which eradication of
all three diseases never occurs. Above this threshold, the
time required to eradicate all three diseases drops shar-
ply. Beyond an annual budget of $190 million, the time
to eradication stabilizes and does not decrease signifi-
cantly as annual budget increases (Figure 4a).
We define an annual budget to be optimal if it
requires the least total expenditure, i.e. the sum of
annual budgets from the time SIAs are implemented
(2010) to the time of eradication is minimized. For the
Figure 3 Time series of vaccination coverage under sequential
strategy. SIA vaccination coverage in India (a), Nigeria (b) and
Afghanistan (c) under the baseline sequential with an annual SIA
budget of $180 million.
Figure 4 Year of eradication as a function of annual budget, 3-
year SIA intervals. Year of eradication as a function of annual SIA
budget under a 3-year SIA interval, for the sequential strategy (a)
and the simultaneous strategy (b).
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$185 million, under which eradication of Diseases A, B
and C occurs by 2018, 2021, and 2027, respectively for a
total of $3.14 billion between 2010 and 2027. For larger
annual budgets, the time to eradication remains the
same, such that eradication of all three diseases can be
achieved by 2027 under annual budgets of $190, $195,
and $200 million. However, the total expenditure
required for each of these annual SIA budgets is higher
at $3.23, $3.32, and $3.40 billion respectively, between
2010 and 2027.
In summary, under the sequential strategy there is a
minimum threshold annual budget required for eradi-
cating all three diseases, and there is also slightly larger
optimal annual budget where all three diseases are era-
dicated for the least aggregate cost over time. Beyond
the optimal annual budget, the incremental gains of
increased annual budget on time to eradication are
small, under our model assumptions.
The impact of annual SIA budget on time to eradica-
tion is qualitatively similar under the simultaneous strat-
egy, with both a minimum threshold annual budget and
an optimal annual budget. However, the time to eradica-
tion is considerably longer for the same or higher
annual budget (Figure 4b). For instance, under the mini-
mal threshold annual budget of $520 million, eradica-
tion of Diseases A and B occurs by 1997 and 2003
respectively, but Disease C is not eradicated until 2297.
For a higher annual budget of $560 million, eradication
of Diseases A, B and C occurs by 1997, 2000 and 2031,
respectively (Figure 4b)-hence, the time to eradication
under the simultaneous strategy is similar to the time to
eradication under the sequential strategy but it requires
a much higher annual budget ($560 versus $180 mil-
lion). If the annual budget under the simultaneous strat-
egy is increased further to $580 million, we obtain the
(non-historical) result that all three diseases are eradi-
cated by 1997, requiring a total of $4.1 billion from
1990 to 1997. This total value of $4.1 billion from 1990
to 1997 under the optimal simultaneous strategy is actu-
ally less than the total value of $6.8 billion from 1990 to
2027 (year of eradication) under the optimal sequential
strategy. Hence, a simultaneous strategy could eradicate
all three diseases more quickly and for less money
expended overall than a sequential strategy, but the
annual budget must be three times higher than usual
($580 million versus $180 million), which may be diffi-
cult to achieve.
Impact of varying SIA scheduling
We next analyze the impact of time interval between
SIAs on the time and budget required to eradicate all
three diseases, under the sequential strategy. If SIAs
occur every two years instead of every three years, there
is still a minimum threshold budget ($220 million)
below which eradication never occurs. Above this
threshold there is very little variation in time to eradica-
tion, as occurred when SIAs were held every three
years. For the optimal budget of $220 million, eradica-
tion of Diseases A, B and C, occur in 2017, 2021, and
2027 respectively (Figure 5a). Utilizing this optimal bud-
get, a 2-year SIA schedule would require a total funding
of $3.74 billion between 2010 and 2027.
If SIAs occur every 4 years, the minimum threshold
budget is $160 million. Above this threshold, there is a
sharp decline in the number of years required for eradi-
cation, but beyond an optimal budget of $180 million,
the time to eradication does not significantly decrease.
This was also a similar pattern as observed with the 3-
year schedule. At the optimal budget of $180 million,
we see that the eradication of Diseases A, B and C
occurs by 2017, 2021, and 2025, respectively, requiring a
total of $2.70 billion.
The optimal annual budgets are $3.74, $3.14, and
$2.70 billion for the 2, 3, and 4-year SIA schedules
respectively; optimal annual budgets are higher for more
frequent SIAs. This occurs because annual budgets are
fixed and hence SIA coverage is a function of the inter-
val between SIAs; for the same budget, SIA vaccine cov-
erage is higher when SIAs are less frequent. A higher
SIA coverage is more likely to push prevalence below
the eradication threshold just after the SIA is completed,
and if SIAs are coordinated and occur simultaneously in
Figure 5 Year of eradication as a function of annual budget
under 2-year and 4-year SIA intervals. Year of eradication as a
function of annual SIA budget for the sequential strategy if SIAs
occur either every 2 years (a) or every 4 years (b).
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ease will be eliminated in all three countries. In contrast,
for a shorter SIA interval (e.g. every 2 years), fewer indi-
viduals are covered during a given SIA and so it is less
likely that incidence will fall below the eradication
threshold immediately following the SIA. This effect
may not occur if SIAs are un-coordinated and occur in
different years in each country, which is the actual prac-
tice. The effect of SIA interval is likely also a function of
how natural immunity develops in the intervals between
SIAs. Finally, these differences apply at the optimal
annual budget: for higher annual budgets such that very
high coverage can be achieved even when SIAs are held
every two years, we expect the time to eradication to be
shorter for more frequent SIAs.
Order of eradication
Our baseline sequential strategy eradicates in the order
D i s e a s eA - B - C ,p a r t l yo nt h eg r o u n d st h a tD i s e a s eA
has the lowest basic reproductive number, R0 =6 ,
meaning that lower vaccine coverage would be required
to eradicate it. Hence, Disease A might represent the
“low hanging fruit” to policy makers. Here we explored
five alternative orders to understand the implications of
ordering for time to eradication: (1) A-C-B, (2) B-C-A,
(3) B-A-C, (4) C-A-B, and (5) C-B-A.
We found that the minimum threshold budget remains
$180 million for each of the five alternative orderings.
The year of eradication for the three diseases under all
six possible orderings under a budget of $180 million is
shown in Table 3. From this table it is clear that Disease
A is eradicated fastest under the four following orderings:
A-B-C, A-C-B, B-A-C, and C-A-B; that is, any order
attempting to eradicate Disease A either first or second
in the series. Disease B is eradicated fastest under either
of the two orders where funding is first allocated towards
its eradication (B-A-C and B-C-A). Under these two
orders, eradication of Disease B can occur in 2015. Simi-
larly, Disease C is eradicated fastest under the orderings
beginning with Disease C: C-A-B and C-B-A.
Interestingly, eradication of all three diseases occurs fast-
est (by 2027) for the order B-C-A or B-A-C, i.e., for stra-
tegies where Disease B is eradicated first (not Disease A
which has the lowest R0). Eradication of all three diseases
takes longest (by 2186) for the order A-C-B and also
takes very long (until 2177) for the order C-A-B, i.e.–
these are strategies where Disease B is eradicated last.
For budgets between $180 and $190 million, the time
to eradication increases a great deal if Disease C is
eliminated before Disease B (Figure 6a). Beyond $190
million, the time to eradication is roughly the same
under all six orderings, such that eradication of all three
diseases is possible by 2027 (Figure 6b). The large differ-
ence in time to eradication for budgets between $180
and $190 million for different orderings may be due to
the high transmissibility of Disease B, which requires
higher coverage to eradicate than Disease A or C. Simi-
larly, any order that aims to eradicate Disease B last
requires the greatest amount of total funding, even
under their respective optimal annual SIA budgets.
It is important to note that while both Disease B and
C are highly transmissible, the basic reproductive num-
ber of Disease B is slightly higher than that of Disease C
(15 and 14, respectively); Disease A has the lowest basic
Table 3 Time to eradication for alternative orderings
under an annual SIA budget of $180 million
Re-allocation order Year of Eradication
Disease A Disease B Disease C
A - B - C 2021 2024 2030
A - C - B 2021 2186 2027
B-C-A 2027 2018 2024
B - A - C 2021 2018 2027
C - A - B 2021 2177 2018
C-B-A 2075 2072 2021
Bold type indicates year that last disease is eradicated under a given
reallocation order.
Figure 6 Change in order of eradication.Y e a ro fe r a d i c a t i o n
under different reallocation orders (A-B-C; A-C-B; B-C-A; B-A-C; C-A-B;
and C-B-A) for the sequential strategy with SIA budgets between
$180 and $190 million (a) and budgets greater than $190 million (b).
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Page 10 of 16reproductive number, 6. Thereby, we propose that trans-
missibility accounts for the difference in time to eradica-
tion seen under each order: eradication occurs more
quickly if the disease with highest transmissibility is era-
dicated first; eradication takes longest in the reverse sce-
nario, where the disease with the lowest transmissibility
is first to eradicated. We have not explored the impact
of natural history and transmissibility assumptions sys-
tematically, hence other conclusions may emerge if
these factors are explored more exhaustively.
Discontinuity in SIA Funding
We examined any possible consequence of an interrup-
tion in SIA funding for the success of the sequential
strategy. We examined three different durations of inter-
ruption-3, 6, and 9 years-each beginning in 2016. During
these periods, SIA coverage was 0% for all three diseases
in all three countries.
As in previous simulations, there is a minimum thresh-
old budget, below which eradication is not possible within
the near future. As for the sequential strategy without
budget interruption, the minimum threshold budget is
$180 million and there is a sharp decline in the number of
years required for eradication above this threshold. Beyond
a budget of $200 million, increases in budget do not trans-
late into significant differences in time to eradication. In
these respects, the results under budget interruption are
qualitatively similar to the results under no interruption.
However, there are quantitative differences: the time to
eradication generally increases under the budget interrup-
tion scenario. For budgets greater than the optimal budget
of $200 million, interruptions of N years translate to
delayed eradication by approximately N years: the baseline
case with no interruption achieves eradication by 2024
under a $220 million budget; the case with a 3-year break
requires 3 extra years for the same $220 million budget,
the case with a 6-year break requires 6 more years for a
$230 million budget, and the case with a 9-year break
requires 9 more years for eradication for a $230 million
budget (Figure 7a). In stark contrast, below the optimal
budget of $200 million, the time to eradication increases
enormously for relatively small interruptions (Figure 7a).
For example, a 3-year break at a budget of $180 million
delays the time to eradication of all three diseases from
2030 to 2080, and the setbacks are even greater for 6-year
and 9-year breaks.
Short-term interruptions in annual SIA budgets can also
have large implications for total required expenditures
from 2010 to eradication. For instance, under a $180 mil-
lion budget, a 3-year interruption would require a total of
$11.70 billion over 68 years (2010-2078) to eradicate all
three diseases. Similarly, a total of $7.38 billion is required
to eradicate over 47 years under a 6-year interruption in
SIA funding, and a total of $25.20 billion is required over
149 years under a 9-year interruption. Without any inter-
ruption in funding, it only takes $3.6 billion over 20 years
(2010-2030) for the same annual budget of $180 million.
A similar pattern is seen when funding is interrupted
in just one country. For instance, in the case of inter-
ruptions only in Nigeria when the usual annual budget
is $230 million, a 3-year interruption again requires 3
extra years, a 6-year interruption again requires 6 more
years, and a 9-year interruption again requires 9 more
years (Figure 7b). This occurs because continued ende-
mic infection in Nigeria can act to seed case imports in
other countries, necessitating continued control efforts
in those countries. For annual SIA budgets below $200
million, a small interruption translates into very long
delays in the time to eradication of all three infections
in all three countries, as was observed in Figure 7a for
the case of interruptions in all three countries. Hence,
budget interruptions in SIA funding for any one country
can have significant implications for time to global era-
dication, especially when budgets are close to the opti-
mal or minimal thresholds. These results echo
experiences with polio elimination in Nigeria, where
there was a cessation of polio immunization between
2002 and 2003 due to a vaccine “scare”.A sar e s u l t ,
Figure 7 SIA funding hiatus. Effect of a break in SIA funding on
year of eradication under different annual budget scenarios.
Funding is entirely cut (SIA vaccination coverage is 0%) for 0, 3, 6
and 9 years in either all three countries (a) or Nigeria only (b). In
each case, the hiatus begins in 2016, and funding re-commences as
normal after the hiatus.
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was detrimentally affected in the whole region [33].
Increasing routine coverage over time
For the results reported thus far in this paper, we
assumed routine vaccination began in 1960 for each of
the three diseases and remained constant at 50% in all
three countries. However, vaccine coverage has been
increasing steadily over the past few decades and are
high for most vaccines in most countries, with a few
exceptions such as Nigeria, India and Afghanistan [23].
To understand the impact of our baseline assumption of
constant vaccine coverage, we repeated the analysis pre-
sented in Figure 4, except that in 2010 routine vaccine
coverage begins to increase additively by 1% per year in
all three countries until coverage reaches 95% in 2055,
after which it remains at 95%.
When routine coverage increases over time, the mini-
mum threshold budget under the sequential strategy is
only $40 million instead of $170 million. As annualbudget
increases beyond this threshold value, the time to eradica-
tion of each disease decreases steadily, and for an annual
budget of $200 million all diseases are eradicated by 2035
(Figure 8a). By comparison, under the simultaneous
strategy, the minimum threshold budget is much larger
($110 million) and the time to eradication decreases only
slightly as the annual SIA budget is increased (Figure 8b).
T h et i m et oe r a d i c a t i o nr e m a i n sv e r yd i f f e r e n tu n d e r
simultaneous versus sequential strategies under the sce-
nario of rising routine vaccine coverage: for an annual
budget of $150, million, Disease A, B, and C are eradicated
by 2038, 2041 and 2047 respectively under the sequential
strategy, but these events occur much later, at 2059, 2074
and 2083 respectively, under the simultaneous strategy.
Hence, even when routine coverage is increasing over
time, budget reallocation strategies such as the sequential
strategy evaluated here can significantly accelerate eradica-
tion of all three infectious diseases compared to a simulta-
neous strategy. We note that these results do not include
the cost of ramping up routine coverage, although
accounting for this would not change our qualitative con-
clusions since the resulting costs would be the same for
the sequential and simultaneous strategy, and routine
immunization would probably continue after eradication.
We also note that exploring whether to allocate funding to
improving routine immunization or implementing more
SIAs in real-world immunization programs would require
a country-specific and disease-specific model.
Case Importation Rate
Here we examine the effects of case importation on the
time to eradication for the baseline sequential strategy
with an annual SIA budget of $180 million. Case impor-
tation has two competing effects on the time to eradica-
tion. On one hand, moderate case importation can
prevent local elimination of a disease: an ongoing epi-
demic in one population can “re-seed” other populations
where the disease might otherwise have disappeared due
to low prevalence, and thus delay elimination in those
populations. On the other hand, sufficiently large rates
of case importation could also synchronize epidemics in
connected populations. As a result, all populations
would experience an epidemic trough at the same time,
meaning that “re-seeding” effects from other populations
would not prevent local elimination in a given popula-
tion. Because all three populations experience epidemic
troughs at the same time and re-seeding is not possible,
the chances of eliminating the infection in all three
populations are higher in this scenario [34].
Because of these two competing effects, the impact of
case importation on time to eradication in our model is
complex. If the case importation rate between the three
countries is higher than our baseline value (m > 0.0001/
year), we observe that all three diseases are eradicated
by 2025 (Figure 9a). Synchronization may contribute to
this effect and is apparent for some of the diseases in
Figure 1. However, for smaller values of the case impor-
tation rate (m < 0.0001/year) the time to eradication
Figure 8 Increasing routine vaccination coverage.Y e a ro f
eradication for a range of annual SIA budgets while routine
coverage increases by 1% each year starting in 2010, until it reaches
95%, for the sequential strategy (a) and the simultaneous strategy
(b).
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delayed until 2100 or 2125. When m =0 ,t h e r ei sn o
case importation, and hence there can be no rescue
effect due to re-seeding, making it easier for eradication
to occur, hence, the time to eradication fall back to
2025 when m = 0 (Figure 9a).
The patterns are even more complex when case
importation is varied for one country at a time. For
example, when the India-Afghanistan and India-Nigeria
case importation rates are changed while the Afghani-
stan-Nigeria case importation rates are held constant at
baseline values, the year of eradication is highly variable
across the range of case importation values explored
(Figure 9b). This variability in year of eradication is even
higher across a range of case importation rates into and
out of Afghanistan (Figure 9d), although the same varia-
bility is not observed across a range of case importation
rates into and out of Nigeria (Figure 9c).
To understand how small changes in case importation
rate can lead to large changes in the time to eradication,
we contrast the scenarios where case importation rates
into and out of India occur at 0.05% per year versus
0.06% per year while other case import rates are held
constant at baseline values (Figure 9b). In Figure 9b we
observed that eradication of all three diseases occurs by
2060 at a rate of 0.05% per year, but it does not occur
until 2168 at a rate of 0.06% per year. In a plot of dis-
ease prevalence over time corresponding to these two
scenarios (Figure 10), we observe that the dynamics of
Disease B are driving these contrasting outcomes. When
case importation occurs at a rate of 0.05% per year, out-
breaks of Disease B in Nigeria and Afghanistan are
highly episodic and appear to be subject to local extinc-
tion (Figure 10a-c). Hence, eradication occurs by 2060.
In comparison, when case importation occurs at 0.06%
per year, outbreaks of Disease B become more regular
and less episodic due to rescue effects, such that when-
ever prevalence is low in Nigeria, prevalence is often
high in Afghanistan and vice versa (Figure 10d-f). As a
result, all three diseases are not eradicated until 2168.
Discussion
Here we analyzed an infectious disease transmission
model where SIA programs for three hypothetical infec-
tious diseases (A, B, C) in Nigeria, Afghanistan and
India share a common budget. A global decision-maker
can allocate differing amounts of money each year out
of the common annual budget to SIA programs for the
Figure 9 Impact of case importation rate. Year of eradication of all three diseases versus case importation rate, under the sequential strategy.
In subpanel (a), importation rates are varied uniformly across all countries. In subpanel (b) case importation rate into and out of India varies
while the migration rates between Nigeria and Afghanistan remain at the baseline value of 0.01% per year; Subpanels (c) and (d) show the same
for Nigeria and Afghanistan respectively.
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age for each program. We compared a “simultaneous
strategy” of dividing the budget equally among SIA pro-
grams each year for the three diseases to a “sequential
strategy” where all annual SIA budget is first allocated
to Disease A until Disease A is eradicated, at which
point all annual SIA budget is redirected to Disease B
until it is eradicated, and then finally to Disease C until
it is eradicated.
We found a broad range of parameter values for
which, under the same annual SIA budget, all three dis-
eases could be eradicated relatively quickly (by 2030)
under the sequential strategy, but none of them could
be eradicated under the simultaneous strategy. Under
the simultaneous strategy, the only way to eradicate all
three diseases on a timescale as rapid as the sequential
strategy was to triple the annual SIA budget–a consider-
able increase in expenditure. Large differences in time
to eradication under the two strategies persisted for a
range of scenarios, including scenarios of both constant
routine coverage and rising routine coverage. We also
found that, for certain values of the total annual budget
close to the optimal values that minimize total long-
term spending, the order of eradication can make a sig-
nificant difference: under the sequential strategy, eradi-
cation of all three diseases happens much more quickly
when Disease B is the first or second disease targeted–if
Disease B is targeted last, eradication of all three dis-
eases does not occur until at least 2177. For certain
values of the budget close to the optimal budget we
f o u n dt h a ta ni n t e r r u p t i o no fS I Af u n d i n go fs e v e r a l
years close to the cusp of eradication can lengthen the
time to eradication by many decades: this outcome can
b es u m m e du pa s“one step back, twenty more steps
back”. These results illustrate how budget allocation
strategies can interact with the inherently nonlinear
dynamics of disease transmission and herd immunity
effects to cause surprisingly divergent outcomes under
moderately different budget allocation strategies. Finally,
we found that the predicted time to eradication was
very sensitive to levels of case importation between the
three countries. We emphasize that our model was sim-
plified in order to illustrate certain principles around
the interaction between budget prioritization and infec-
tious disease dynamics, and is not intended for direct
use in policy considerations. For policy considerations, it
would be necessary to develop a country-specific and
disease-specific approach.
Our objective was to illustrate how the nonlinearities
of disease transmission (and herd immunity in particu-
lar) can amplify relatively modest changes in near-term
budget allocations, resulting in enormous long-term
Figure 10 Time series for similar case importation rates. Prevalence of the three diseases over time in the sequential strategy, given a case
importation rate of 0.05% per year into and out of India, for India (a), Nigeria (b) and Afghanistan (c), and given a case importation rate into and
out of India is 0.06% per year for India (d), Nigeria (e) and Afghanistan (f). These two scenarios correspond to that of Figure 9b, where other case
importation rates are held constant at baseline value of 0.01% per year.
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Page 14 of 16differences in disease prevalence. Our objective was not
to provide a tool that could be used to inform specific
policies. This would require greater attention to factors
such as transmission heterogeneity and seasonality; a
broader spectrum of costs including opportunity costs
and costs of treating infections and controlling out-
breaks; a broader spectrum of health outcomes includ-
ing use of disability-adjusted-life-years (DALYs) to allow
sensible comparison between different strategies and dif-
ferent diseases in terms of total disease burden; the fact
that cancelling SIAs for a given disease may not always
be possible or desirable due to use of combined vaccines
or joint administration of control programs; judicious
use of discounting to weigh tradeoffs between short-
term versus long-term outcomes in different birth
cohorts; possible ethical concerns related to the
increased incidence of all other diseases in the short
term while funding goes specifically to the eradication
one disease alone; higher vaccine unit costs required to
reach the last remaining reservoirs of transmission
(populations) that tend to be harder to reach; cost sav-
ings in simultaneous strategies due to being able to
administer multiple vaccines in the same SIA; and
incorporation of “hard restrictions” on how international
donors support SIA programs. Another limitation of our
model is that it is not age-structured with respect to
transmission or vaccination target groups. Including age
structure could impact the required threshold for eradi-
cation, or inform eradication strategies such as optimal
target age groups for SIAs [35]. Future studies incorpor-
ating age-structure could therefore refine our results.
However, we suggest that many of the nonlinear effects
such as herd immunity will be conserved under more
sophisticated treatments of this problem, which would
thus exhibit similar amplification effects as observed
here.
More sophisticated models could also be used to
compare control measures for diseases with different
modalities of transmission, such as measles versus
malaria versus human immunodeficiency virus (HIV).
Our model only applies to diseases that are trans-
mitted through direct contact, i.e., person to person.
Its results may not apply to diseases that can be trans-
mitted through indirect contact (such as through
infected food or water). The model also assumes
homogeneous mixing, which does not apply at the
country level. As a result, the predicted dynamics
could differ from those of a model where a country is
broken down into mixing subpopulations. Many of
t h e s ei s s u e sc o u l db ea d d r e s s e di nf u t u r ew o r k ,a n da
possible application of more sophisticated versions of
this type of model is optimizing the portfolios of large
international donors.
Conclusions
We found that re-allocating budget among SIA pro-
grams for three hypothetical infectious paediatric dis-
eases under a sequential eradication strategy can
significantly speed eradication of all three diseases for
t h es a m ea n n u a lS I Ab u d g e t ,u n d e rar a n g eo fm o d e l
assumptions. Moreover, relatively modest differences in
budget allocation in the near-term can result in very sig-
nificant long-term differences in outcomes– particularly
the time to eradication–as a result of the amplifying
effects of herd immunity and the nonlinearities of dis-
ease transmission. More sophisticated versions of such
models may be useful to large international donors or
other organizations as a planning tool or a tool for port-
folio optimization, where choices must be made regard-
ing how much funding to dedicate to different
infectious disease eradication efforts.
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